Sitari

Sitari Pharmaceuticals was founded in 2013, with its headquarters located in San Diego, California, USA. It is a biotechnology and pharmaceutical company. Jointly established by GSK and Avalon Ventures, a venture capital firm in the life sciences sector, the company is committed to developing TG2 inhibitors for creating new therapies targeting autoimmune diseases related to the human digestive system. The company believes that targeted inhibition of TG2 can reduce autoimmune diseases triggered by proteins, thereby treating intestinal inflammation, celiac disease, and its complications.